Biography:Nicholas Lydon

From HandWiki
Short description: British biochemist


Nicholas Lydon
Nicholas Lydon.jpg
Born (1957-02-27) 27 February 1957 (age 67) [citation needed]
Alma mater
Known for
  • Gleevec
  • AnaptysBio
  • BluePrint Medicines
Awards
  • Lasker Clinical Award (2009)
  • Japan Prize (2012)
  • FRS (2013)
Scientific career
Institutions
ThesisStudies on the hormone-sensitive adenylate cyclase from bovine corpus luteum (1982)
Websiteroyalsociety.org/people/nicholas-lydon

Nicholas B. Lydon FRS (born 27 February 1957) is a British scientist and entrepreneur.[1] In 2009, he was awarded the Lasker Clinical Award and in 2012 the Japan Prize for the development of Gleevec, also known as Imatinib, a selective BCR-ABL inhibitor for the treatment of chronic myeloid leukaemia (CML), which converted a fatal cancer into a manageable chronic condition.[2][3][4][5] [6][7]

Education

Lydon was educated at Strathallan School near Perth, Scotland.[8] He earned a Bachelor of Science degree in biochemistry from the University of Leeds, England in 1978 and received his PhD in biochemistry from the University of Dundee, Scotland in 1982.[8][9]

Career

In 1982, Lydon accepted a position with Schering-Plough based in France as Chargé de Récherche.[3] Three years later, he moved to Switzerland to work with Ciba-Geigy Pharmaceuticals, with whom he developed Gleevec.[8] In 1997, he established Kinetex Pharmaceuticals in Boston which was acquired by Amgen in 2000, with whom he worked until 2002.[8] Thereafter, he established several companies that continue to develop drugs to treat various conditions.[8]

Honours and awards

  • Warren Alpert Foundation Prize, 2000.[3]
  • Twenty First Annual AACR-Bruce F. Cain Memorial Award, 2002.[3]
  • Charles F. Kettering Prize, General Motors Cancer Research Foundation, 2002.[3]
  • The Lasker-DeBakey Clinical Medical Research Award, with Brian Druker and Charles Sawyers, 2009.[3]
  • The Japan Prize, with Brian Druker and Janet Rowley, 2012.[3]
  • Fellow of the Royal Society, 2013.[10]
  • Royal Society GlaxoSmithKline Prize and Lecture, 2014[11]

Lydon's nomination for the Royal Society reads:

References

  1. "Nicholas Lydon". 2010. http://www.scienceheroes.com/index.php?option=com_content&view=article&id=379&Itemid=312. 
  2. "Lasker – DeBakey Clinical Medical Research Award: Award Description". Lasker Foundation. http://www.laskerfoundation.org/awards/2009_c_description.htm. 
  3. 3.0 3.1 3.2 3.3 3.4 3.5 3.6 "Laureates of the Japan Prize". The Japan Prize Foundation. 2012. http://www.japanprize.jp/en/prize_prof_2012_b_lydon.html. 
  4. Druker, B. J.; Talpaz, M.; Resta, D. J.; Peng, B.; Buchdunger, E.; Ford, J. M.; Lydon, N. B.; Kantarjian, H. et al. (2001). "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia". New England Journal of Medicine 344 (14): 1031–1037. doi:10.1056/NEJM200104053441401. PMID 11287972. 
  5. List of publications from Microsoft Academic
  6. Druker, B. J.; Tamura, S.; Buchdunger, E.; Ohno, S.; Segal, G. M.; Fanning, S.; Zimmermann, J.; Lydon, N. B. (1996). "Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells". Nature Medicine 2 (5): 561–566. doi:10.1038/nm0596-561. PMID 8616716. 
  7. Buchdunger, E.; Cioffi, C. L.; Law, N.; Stover, D.; Ohno-Jones, S.; Druker, B. J.; Lydon, N. B. (2000). "Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors". The Journal of Pharmacology and Experimental Therapeutics 295 (1): 139–145. PMID 10991971. 
  8. 8.0 8.1 8.2 8.3 8.4 "Dr Nicholas Lydon". University of Dundee. 2011. http://www.ppu.mrc.ac.uk/resources/Nick_Lydon_Laureation.doc. 
  9. Lydon, Nicholas B. (1982). Studies on the hormone-sensitive adenylate cyclase from bovine corpus luteum (PhD thesis). University of Dundee. Cite has empty unknown parameter: |1= (help)(Subscription content?)
  10. 10.0 10.1 "Dr Nicholas Lydon". Royal Society. 2013. http://royalsociety.org/people/nicholas-lydon/. 
  11. "GlaxoSmithKline prize". Royal Society. http://royalsociety.org/awards/glaxosmithkline-prize-lecture/.